We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Automated Urine Analyzer Offers Fast, Sensitive and Precise AST in Near-Patient Settings

By LabMedica International staff writers
Posted on 26 Apr 2023
Print article
Image: PA-100 AST System (Photo courtesy of Sysmex Europe)
Image: PA-100 AST System (Photo courtesy of Sysmex Europe)

Urinary tract infections (UTIs) are highly prevalent infectious diseases, impacting an estimated 150 million people worldwide. Typically, these infections are treated with antimicrobial drugs. To determine the appropriate medication, healthcare professionals must conduct bacteria identification tests and drug susceptibility tests alongside clinical findings. However, these tests often take days to complete, making it challenging to prescribe the right antimicrobial drugs during the first consultation. Consequently, this can lead to the prescription of improper medications and contribute to the development of antimicrobial resistance.

The PA-100 AST System from Sysmex Europe SE (Norderstedt, Germany) is an innovative automated urine analyzer that expedites antimicrobial susceptibility testing (AST) at the point of care. By combining phase contrast microscopy and nanofluidics, the system generates antibiograms at the point of care. The cutting-edge nanofluidics-based technology ensures exceptional diagnostic performance. User-friendly and efficient, the PA-100 AST System can determine bacterial growth and AST in under an hour, with results conforming to EUCAST standards.

Employing lab-on-a-chip technology, the PA-100 AST System rapidly and automatically analyzes urine samples, optimizing workflow and providing results during a patient's initial visit to the physician. This breakthrough technology brings diagnostics to outpatient clinics, supporting evidence-based medication where extensive antibiotic prescriptions are common. By facilitating antibiotic prescription decisions in less than an hour, the system helps circumvent empirical treatment and curtail the spread of antimicrobial resistance.

Related Links:
Sysmex Europe SE 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.